Literature DB >> 16584119

Molecular recognition of opioid receptor ligands.

Brian E Kane1, Bengt Svensson, David M Ferguson.   

Abstract

The cloning of the opioid receptors and subsequent use of recombinant DNA technology have led to many new insights into ligand binding. Instead of focusing on the structural features that lead to increased affinity and selectivity, researchers are now able to focus on why these features are important. Site-directed mutagenesis and chimeric data have often been at the forefront in answering these questions. Herein, we survey pharmacophores of several opioid ligands in an effort to understand the structural requirements for ligand binding and selectivity. Models are presented and compared to illustrate key sites of recognition for both opiate and nonopiate ligands. The results indicate that different ligand classes may recognize different sites within the receptor, suggesting that multiple epitopes may exist for ligand binding and selectivity.

Mesh:

Substances:

Year:  2006        PMID: 16584119      PMCID: PMC2751431          DOI: 10.1208/aapsj080115

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  66 in total

Review 1.  Opioid receptor types and subtypes: the delta receptor as a model.

Authors:  P A Zaki; E J Bilsky; T W Vanderah; J Lai; C J Evans; F Porreca
Journal:  Annu Rev Pharmacol Toxicol       Date:  1996       Impact factor: 13.820

2.  [3H]U-69593 a highly selective ligand for the opioid kappa receptor.

Authors:  R A Lahti; M M Mickelson; J M McCall; P F Von Voigtlander
Journal:  Eur J Pharmacol       Date:  1985-02-26       Impact factor: 4.432

3.  Bimorphinans as highly selective, potent kappa opioid receptor antagonists.

Authors:  A S Portoghese; A W Lipkowski; A E Takemori
Journal:  J Med Chem       Date:  1987-02       Impact factor: 7.446

4.  A chimeric study of the molecular basis of affinity and selectivity of the kappa and the delta opioid receptors. Potential role of extracellular domains.

Authors:  F Meng; M T Hoversten; R C Thompson; L Taylor; S J Watson; H Akil
Journal:  J Biol Chem       Date:  1995-05-26       Impact factor: 5.157

Review 5.  Molecular biology and pharmacology of cloned opioid receptors.

Authors:  R J Knapp; E Malatynska; N Collins; L Fang; J Y Wang; V J Hruby; W R Roeske; H I Yamamura
Journal:  FASEB J       Date:  1995-04       Impact factor: 5.191

6.  Structure-activity relationships for SNC80 and related compounds at cloned human delta and mu opioid receptors.

Authors:  R J Knapp; G Santoro; I A De Leon; K B Lee; S A Edsall; S Waite; E Malatynska; E Varga; S N Calderon; K C Rice; R B Rothman; F Porreca; W R Roeske; H I Yamamura
Journal:  J Pharmacol Exp Ther       Date:  1996-06       Impact factor: 4.030

7.  Analysis of selective binding epitopes for the kappa-opioid receptor antagonist nor-binaltorphimine.

Authors:  S A Hjorth; K Thirstrup; D K Grandy; T W Schwartz
Journal:  Mol Pharmacol       Date:  1995-06       Impact factor: 4.436

8.  -mu opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity.

Authors:  C K Surratt; P S Johnson; A Moriwaki; B K Seidleck; C J Blaschak; J B Wang; G R Uhl
Journal:  J Biol Chem       Date:  1994-08-12       Impact factor: 5.157

9.  Human kappa opiate receptor second extracellular loop elevates dynorphin's affinity for human mu/kappa chimeras.

Authors:  J B Wang; P S Johnson; J M Wu; W F Wang; G R Uhl
Journal:  J Biol Chem       Date:  1994-10-21       Impact factor: 5.157

10.  The third extracellular loop of the mu opioid receptor is important for agonist selectivity.

Authors:  J C Xue; C Chen; J Zhu; S P Kunapuli; J K de Riel; L Yu; L Y Liu-Chen
Journal:  J Biol Chem       Date:  1995-06-02       Impact factor: 5.157

View more
  17 in total

Review 1.  Ligand-directed signalling within the opioid receptor family.

Authors:  Amynah A Pradhan; Monique L Smith; Brigitte L Kieffer; Christopher J Evans
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

2.  Quantitative conformationally sampled pharmacophore for delta opioid ligands: reevaluation of hydrophobic moieties essential for biological activity.

Authors:  Denzil Bernard; Andrew Coop; Alexander D MacKerell
Journal:  J Med Chem       Date:  2007-03-17       Impact factor: 7.446

3.  Docking studies suggest ligand-specific delta-opioid receptor conformations.

Authors:  Vuk Micovic; Milovan D Ivanovic; Ljiljana Dosen-Micovic
Journal:  J Mol Model       Date:  2008-12-04       Impact factor: 1.810

4.  "Carba"-analogues of fentanyl are opioid receptor agonists.

Authors:  Grazyna Weltrowska; Nga N Chung; Carole Lemieux; Jianxin Guo; Yixin Lu; Brian C Wilkes; Peter W Schiller
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

5.  Allosteric modulation model of the mu opioid receptor by herkinorin, a potent not alkaloidal agonist.

Authors:  A F Marmolejo-Valencia; K Martínez-Mayorga
Journal:  J Comput Aided Mol Des       Date:  2017-03-31       Impact factor: 3.686

Review 6.  The delta opioid receptor: an evolving target for the treatment of brain disorders.

Authors:  Amynah A Pradhan; Katia Befort; Chihiro Nozaki; Claire Gavériaux-Ruff; Brigitte L Kieffer
Journal:  Trends Pharmacol Sci       Date:  2011-09-17       Impact factor: 14.819

7.  Design, synthesis, and validation of a β-turn mimetic library targeting protein-protein and peptide-receptor interactions.

Authors:  Landon R Whitby; Yoshio Ando; Vincent Setola; Peter K Vogt; Bryan L Roth; Dale L Boger
Journal:  J Am Chem Soc       Date:  2011-06-15       Impact factor: 15.419

Review 8.  Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits.

Authors:  Michael Camilleri; Anthony Lembo; David A Katzka
Journal:  Clin Gastroenterol Hepatol       Date:  2017-05-19       Impact factor: 11.382

9.  Identification, structure-activity relationships and molecular modeling of potent triamine and piperazine opioid ligands.

Authors:  Austin B Yongye; Jon R Appel; Marc A Giulianotti; Colette T Dooley; Jose L Medina-Franco; Adel Nefzi; Richard A Houghten; Karina Martínez-Mayorga
Journal:  Bioorg Med Chem       Date:  2009-06-21       Impact factor: 3.641

10.  Caged naloxone reveals opioid signaling deactivation kinetics.

Authors:  Matthew R Banghart; John T Williams; Ruchir C Shah; Luke D Lavis; Bernardo L Sabatini
Journal:  Mol Pharmacol       Date:  2013-08-19       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.